Article Text

FRI0208 Prediction of treatment response of tocilizumab for rheumatoid arthritis with comprehensive gene expression analysis in peripheral blood mononuclear cells
  1. Y. Sanayama1,
  2. K. Ikeda1,
  3. S. Kagami1,
  4. S. Furuta2,
  5. D. Kashiwakuma2,
  6. I. Matsuura2,
  7. M. Yamagata2,
  8. I. Iwamoto2,
  9. T. Umibe3,
  10. R. Matsumura4,
  11. T. Sugiyama5,
  12. M. Sueishi5,
  13. Y. Nawata6,
  14. M. Hiraguri7,
  15. K. Nonaka8,
  16. O. Ohara8,
  17. H. Nakajima1
  1. 1Allergy and Clinical Immunology, Chiba University Hospital, Chiba
  2. 2Asahi General Hospital, Asahi
  3. 3Matsudo City Hospital, Matsudo
  4. 4National Hospital Organization Chiba-East-Hospital, Chiba
  5. 5National Hospital Organization Shimoshizu Hospital, Yotsukaido
  6. 6Chibaken Saiseikai Narashino Hospital, Narashino
  7. 7Japanese Red Cross Narita Hospital, Narita
  8. 8Kazusa DNA Research Institute, Kisarazu, Japan


Background Tocilizumab (TCZ) is a biological agent which is highly efficacious for rheumatoid arthritis (RA). Although predicting treatment response to TCZ can be especially beneficial since TCZ takes longer time to demonstrate its efficacy as compared with anti-TNFa agents, such methods have not been established. On the other hand, previous reports showed usefulness of DNA array analysis of peripheral blood to predict clinical response to infliximab in RA.

Objectives To establish methods to predict clinical response to TCZ therapy with comprehensive gene expression analysis of peripheral blood mononuclear cells (PBMCs) in patients with RA.

Methods A total of 18 patients who received TCZ for inadequately controlled RA (CDAI >10) were analyzed as a training cohort. RNA was extracted from PBMCs before the first administration of TCZ and was analyzed for comprehensive gene expression using Human Whole Genome 4×44K format. Clinical response was assessed over six months using CDAI category improvement and physician’s global assessment.

Results At six months of TCZ treatment, responders and non-responders were identified with two different measures (13 responders and three non-responders for CDAI category improvement; 14 responders and three non-responders for physician’s global assessment). For each response measure, 20 probes were extracted which demonstrated lowest t-test P values for difference in normalized signals between responders and non-responders and also demonstrated >1.5 fold difference between responders and non-responders. 19 common probes between these two response measures were identified, all of which represented a distinctive gene. Clustering analysis of these genes in the training cohort showed a characteristic pattern for non-responders (figure). A prediction model using these genes with a cut-off signal for each probe completely discriminated non-responders from responders in the training cohort.

Figure 1. Expression patterns and clustering of 19 selective genes.

Conclusions Comprehensive gene expression analysis of PBMCs provided a promising result in developing methods to predict clinical response to TCZ therapy for RA.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.